- Home
- GNLX vs ASRT Comparison
GNLX vs ASRT Comparison
Compare GNLX & ASRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNLX
- ASRT
- Stock Information
- Founded
- GNLX 2001
- ASRT 1995
- Country
- GNLX United States
- ASRT United States
- Employees
- GNLX N/A
- ASRT N/A
- Industry
- GNLX Biotechnology: Pharmaceutical Preparations
- ASRT Biotechnology: Pharmaceutical Preparations
- Sector
- GNLX Health Care
- ASRT Health Care
- Exchange
- GNLX Nasdaq
- ASRT Nasdaq
- Market Cap
- GNLX 112.5M
- ASRT 57.9M
- IPO Year
- GNLX 2023
- ASRT 1997
- Fundamental
- Price
- GNLX $3.44
- ASRT $0.69
- Analyst Decision
- GNLX Strong Buy
- ASRT Strong Buy
- Analyst Count
- GNLX 4
- ASRT 2
- Target Price
- GNLX $17.75
- ASRT $3.25
- AVG Volume (30 Days)
- GNLX 152.2K
- ASRT 259.0K
- Earning Date
- GNLX 08-13-2025
- ASRT 08-06-2025
- Dividend Yield
- GNLX N/A
- ASRT N/A
- EPS Growth
- GNLX N/A
- ASRT N/A
- EPS
- GNLX N/A
- ASRT N/A
- Revenue
- GNLX N/A
- ASRT $119,001,000.00
- Revenue This Year
- GNLX N/A
- ASRT N/A
- Revenue Next Year
- GNLX N/A
- ASRT $11.91
- P/E Ratio
- GNLX N/A
- ASRT N/A
- Revenue Growth
- GNLX N/A
- ASRT N/A
- 52 Week Low
- GNLX $1.60
- ASRT $0.51
- 52 Week High
- GNLX $5.89
- ASRT $1.80
- Technical
- Relative Strength Index (RSI)
- GNLX 65.71
- ASRT 64.38
- Support Level
- GNLX $2.80
- ASRT $0.63
- Resistance Level
- GNLX $3.61
- ASRT $0.67
- Average True Range (ATR)
- GNLX 0.22
- ASRT 0.03
- MACD
- GNLX 0.05
- ASRT 0.01
- Stochastic Oscillator
- GNLX 80.23
- ASRT 86.37
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.
About ASRT Assertio Holdings Inc.
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older and Zipsor, liquid-filled capsules for relief of mild to moderate pain.